MiMedx Group (NASDAQ: MDXG) and Haemonetics Corporation (NYSE:HAE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Institutional & Insider Ownership

60.4% of MiMedx Group shares are owned by institutional investors. 12.4% of MiMedx Group shares are owned by insiders. Comparatively, 1.2% of Haemonetics Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares MiMedx Group and Haemonetics Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MiMedx Group 7.48% 15.95% 11.13%
Haemonetics Corporation 0.48% 11.07% 6.54%

Analyst Ratings

This is a breakdown of current ratings for MiMedx Group and Haemonetics Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group 1 0 3 1 2.80
Haemonetics Corporation 1 3 3 0 2.29

MiMedx Group currently has a consensus price target of $16.00, indicating a potential upside of 31.96%. Haemonetics Corporation has a consensus price target of $41.17, indicating a potential downside of 11.11%. Given MiMedx Group’s stronger consensus rating and higher probable upside, equities analysts clearly believe MiMedx Group is more favorable than Haemonetics Corporation.

Risk & Volatility

MiMedx Group has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Haemonetics Corporation has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares MiMedx Group and Haemonetics Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
MiMedx Group $283.32 million 4.59 $32.97 million $0.19 63.82
Haemonetics Corporation $887.11 million 2.75 $164.54 million $0.08 578.95

Haemonetics Corporation has higher revenue and earnings than MiMedx Group. MiMedx Group is trading at a lower price-to-earnings ratio than Haemonetics Corporation, indicating that it is currently the more affordable of the two stocks.

Summary

MiMedx Group beats Haemonetics Corporation on 11 of the 14 factors compared between the two stocks.

MiMedx Group Company Profile

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Receive News & Stock Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related stocks with our FREE daily email newsletter.